Quality assurance

Each of the four Universities has a full quality assurance plan running, with both internal and external bodies that participate in the quality assurance process (Università del Piemonte Orientale; Universitas Miguel Hernandez; Humboldt-Universitat zu Berlin). Alongside those already in place in the three Universities, the following bodies are created to ensure quality and governance of EMOTION programme.

Joint Consortium Board (JCB)

It has the core responsibility for the management of the Programme and oversees the running of EMOTION. The JCB is the forum at which all questions of Programme-specific policy will be discussed, and recommendations will be formulated. It deals with all academic issues, Programme development and promotion, quality procedures, strategic planning, harmonization of procedures among institutions and the principles of economy and administration. The JCB is formed by one representative from each partner institution and is chaired by the representative of the Coordinating Institution (Programme Coordinator). The Joint Consortium Board meets in person once a year.

External Advisory Board

It represents the industry stakeholders and internationally recognized experts in the field of cosmetic and dermatological sciences. This board gives non-binding judgements on EMOTION structure and contents, and provides advice aimed at ensuring the excellence of the Programme. It is composed of 6 members that meet at least once yearly. It is named by the JCB.

FEDERICA BORSA

She graduated in International Relations at the University of Milan. The Erasmus project at the Institut d’Etudes Politique in Grenoble/France allowed her to study the French language and culture and to get in touch with a multicultural and international reality. She completed her training by attending, in 2005, the Master of Business Administration with a concentration in Foreign Trade held at the Italian Trade Agency in Rome, thus studying the dynamics of international trade and internationalization processes. In 2006, she carried out an internship abroad at the headquarter of the Italian Trade Commission in Mumbai, India, which allowed her to get to know and deepen the Indian economic and commercial reality. Since 2006 she has been working in Cosmetica Italia, the personal care association, first in the International Relations Area planning and coordinating the international activities and promotion for associated cosmetic companies creating opportunities in foreign markets, and, since 2015, as Project Manager with the responsibility of the Education and Sustainability Projects of the Association, coordinating collaborations with universities, secondary schools and other institutions, public or private, to enhance the reputation of the industry and of the cosmetic product and to promote, organize and implement training activities and managing the Sustainability project of the Cosmetica Italia to enhance and spread sustainability culture among associate firms.

MABEL LOZA

She is Professor of Pharmacology and head of BioFarma pharmacology research group at the University of Santiago de Compostela. She is Leader in the field of Early Drug Discovery at Spanish and European levels, endorsed by the participation in more than 89 research programs as principal investigator, founded by public and private institutions. She has actively participated in the development of 14 NCE that have reached clinical trials in the specific programmes of R&D transfer in drug development of different pharmaceutical companies. She is author of more than 10 books and book chapters, 160 articles in indexed journals in the Journal Citation Report. She has actively participated in the development of networks and new models of open innovation in early drug discovery: coordinator of the Drug Discovery Galician Network (2007-onwards) and the Drug Discovery Spanish Network of Excellence (REDEFAR). Node coordinator and Spanish Scientific representative of EU-Openscreen ESFRI/ERIC. She is coordinator from the public side of the Joint Research Unit USC/Esteve: intensive collaboration with industry with 5 years of experience in the development of innovation in early drug discovery. She also co-coordinates INNOPHARMA project (EU-Technological funded) Board of trustees of Kæertor Foundation, for nonprofit foundation for promoting reciprocal transference in open innovation in drug discovery. She is member of the Coordination Committee of the Spanish Technological Platform for Innovative Medicines. She is representative of the University of Santiago de Compostela on the Board of the Ramón Domínguez Foundation for the Research, Development and Innovation. She is also full academician of the Galician Academy of Pharmacy. As entrepreneur, she has promoted the foundation of three companies (Pharmatools Digital Interactive SL, Allelyus and Oncostellae). She has been selected as one of the “30 scientists from 30 countries in Europe” of the Portraits of Science-Scientists of Tomorrow Initiative, in the 30th anniversary of the European Federation of Pharmaceutical Industries and Associations (EFPIA). She was recognized with the Innovative Researcher 2018 award by the FEI Recognitions.

LORENZO POLENZANI

He conducted research activities in cardiovascular diseases area at the Department of Preclinical and Clinical Pharmacology University of Florence. In 1988 he moved to University of California Irvine (USA) studying GABA receptors by means of molecular biology and electrophysiological techniques. Back to Italy in 1992, after a brief experience at the Biophysics Lab of the Cancer Institute Regina Elena Rome, he joined Angelini in 1993 as Head of the Molecular and Cellular Pharmacology Lab. In 2001 he became the Therapeutic Area Team leader of Analgesic and Anti-inflammatory products and then R&D Pipeline Strategy Manager. Since 2016, he is the Head of the Scientific Networking and Competitive Intelligence Unit of the Angelini’s RR&D (Research Regulatory and Development) looking for and evaluating innovative solutions and technological platforms to be considered for research collaboration and licensing operations. Member of the Italian Society of Pharmacology (SIF) and International Association for the Study of Pain (IASP).

YVES GEYSELS

Yves Geysels is Visiting Professor of Clinical Trials at the Faculty of Medicine, Department of Biomedical Sciences and has authored more than 50 publications. Currently he is also Director of Clinical Operations at Bone Therapeutics, a bone cell therapy company, specializing in addressing unmet medical needs in the field of orthopaedics and bone diseases. Yves has a vast experience of more than 20 years in managing clinical trials from an operational point of view, within pharmaceutical companies and Contract Research Organizations (CRO), prior joining the Biotech Industry in 2018. He is founder and honorary president of the Belgian Association of Clinical Research Professionals (ACRP.be) and a honorary fellow at the University of Brussels (VUB).

CRISTINA CARREÑO

Dr. Cristina Carreño is the Business Development Director of Lipotec, the active ingredients division of Lubrizol. She received her PhD in Organic Chemistry from the University of Barcelona in 1997, where she specialized in both peptide and combinatorial chemistry. For nine years she was in charge of the Peptide Synthesis Facility at the University of Barcelona, after which she joined to DiverDrugs, the research company of Lipotec Group. Initially focused on the discovery of new active ingredients for the pharmaceutical field, from 2004 to 2011 she was responsible of the development of new active ingredients for cosmetic applications. Since 2008 she combined her activities in DiverDrugs with the development of new business for Lipotec on a global basis, managing strategic collaborations with regional and global cosmetic companies. Since end 2011 she works for Lipotec on an exclusive basis, being accountable for accelerating the active ingredients business and for the continuous education program for Lubrizol marketing and sales force in the Beauty division. Dr. Carreño is the author of several patents in the field of new actives for cosmetic dermatology.

CLAIRE DACHELET

Claire Dachelet, MD, was graduated from the faculty of medicine and obtained the complementary master of Dermato-Venereology in 1998 (University of Namur and University Catholic of Louvain UCL – Brussels). During her residency, she worked in the Laboratory of Dermatology for the diagnosis of autoimmune bullous diseases, connective tissue diseases and vasculitis. She was trained as a research fellow at the University of Washington, Seattle in 1997-1998. She obtained in 2010 a DU in Infectious and Tropical Dermatology from the University Pierre and Marie Curie, Paris. In 1998, she joined the UCL Laboratory of Dermatology and developed the diagnosis of auto-immune skin diseases. She started a clinical activity at the CHU of Mont-Godinne. In 2006, she became the head of the department of Dermatology of the CHU UCL Namur – Godinne. Currently, she has been working for the CHU UCL Namur and for the Anatomical Pathology Laboratory of UCL. She is a dermatology training master for 6 years.

Her main fields of activity are:

  • Autoimmune bullous diseases
  • Auto-immune and auto-inflammatory diseases
  • Immunocompromised patients
  • Infectious and tropical dermatology

Student – Academic Staff Committee (SASC)

It is composed of three members of academic staff (one from each institution) and three elected students per each intake. It is called upon in two ways: (i) students use this Committee to bring formally to the attention issues to the management; (ii) the Committee gives a non-binding judgement on the changes proposed by the JCB. Student elections will be overseen by the JCB. SACS meets once a year.

Secretariat

It deals with the management of the course, regarding economic, administrative and practical issues of EMOTION. It is responsible for the Programme website, processes all applications, organizes the Joint Admission Board and the Joint Examination Board, prepares the joint diploma supplement, coordinates the production of the promotion/dissemination material. A Project Manager, member of the administration of UPO, is formally appointed to manage the Master from an institutional point of view, coordinates  the Secreteriat and is assisted by a junior Project Manager that will work specifically on EMOTION. The Project Manager may be co-opted as a non-voting member in the JCB. HU and UMH name technical support staff members that lease with the secretariat regarding general management issues and deal with specific issues of the teaching held in the respective Institutions. The secretariat meets UH and UMH technical support staff members in person or through electronically-mediated systems at least once per year.

Alongside, a number of activities through the year will take place to ensure quality assurance, excellence and continuous improvement of the course (e.g. student feedback at the end of each lesson and/or teaching module; alumni questionnaire).

Quality assurance

Each of the four Universities has a full quality assurance plan running, with both internal and external bodies that participate in the quality assurance process (Università del Piemonte Orientale; Universitas Miguel Hernandez; Humboldt-Universitat zu Berlin). Alongside those already in place in the three Universities, the following bodies are created to ensure quality and governance of EMOTION programme.

Joint Consortium Board (JCB)

It has the core responsibility for the management of the Programme and oversees the running of EMOTION. The JCB is the forum at which all questions of Programme-specific policy will be discussed, and recommendations will be formulated. It deals with all academic issues, Programme development and promotion, quality procedures, strategic planning, harmonization of procedures among institutions and the principles of economy and administration. The JCB is formed by one representative from each partner institution and is chaired by the representative of the Coordinating Institution (Programme Coordinator). The Joint Consortium Board meets in person once a year.

External Advisory Board

It represents the industry stakeholders and internationally recognized experts in the field of cosmetic and dermatological sciences. This board gives non-binding judgements on EMOTION structure and contents, and provides advice aimed at ensuring the excellence of the Programme. It is composed of 6 members that meet at least once yearly. It is named by the JCB.

FEDERICA BORSA

She graduated in International Relations at the University of Milan. The Erasmus project at the Institut d’Etudes Politique in Grenoble/France allowed her to study the French language and culture and to get in touch with a multicultural and international reality. She completed her training by attending, in 2005, the Master of Business Administration with a concentration in Foreign Trade held at the Italian Trade Agency in Rome, thus studying the dynamics of international trade and internationalization processes. In 2006, she carried out an internship abroad at the headquarter of the Italian Trade Commission in Mumbai, India, which allowed her to get to know and deepen the Indian economic and commercial reality. Since 2006 she has been working in Cosmetica Italia, the personal care association, first in the International Relations Area planning and coordinating the international activities and promotion for associated cosmetic companies creating opportunities in foreign markets, and, since 2015, as Project Manager with the responsibility of the Education and Sustainability Projects of the Association, coordinating collaborations with universities, secondary schools and other institutions, public or private, to enhance the reputation of the industry and of the cosmetic product and to promote, organize and implement training activities and managing the Sustainability project of the Cosmetica Italia to enhance and spread sustainability culture among associate firms.

MABEL LOZA

She is Professor of Pharmacology and head of BioFarma pharmacology research group at the University of Santiago de Compostela. She is Leader in the field of Early Drug Discovery at Spanish and European levels, endorsed by the participation in more than 89 research programs as principal investigator, founded by public and private institutions. She has actively participated in the development of 14 NCE that have reached clinical trials in the specific programmes of R&D transfer in drug development of different pharmaceutical companies. She is author of more than 10 books and book chapters, 160 articles in indexed journals in the Journal Citation Report. She has actively participated in the development of networks and new models of open innovation in early drug discovery: coordinator of the Drug Discovery Galician Network (2007-onwards) and the Drug Discovery Spanish Network of Excellence (REDEFAR). Node coordinator and Spanish Scientific representative of EU-Openscreen ESFRI/ERIC. She is coordinator from the public side of the Joint Research Unit USC/Esteve: intensive collaboration with industry with 5 years of experience in the development of innovation in early drug discovery. She also co-coordinates INNOPHARMA project (EU-Technological funded) Board of trustees of Kæertor Foundation, for nonprofit foundation for promoting reciprocal transference in open innovation in drug discovery. She is member of the Coordination Committee of the Spanish Technological Platform for Innovative Medicines. She is representative of the University of Santiago de Compostela on the Board of the Ramón Domínguez Foundation for the Research, Development and Innovation. She is also full academician of the Galician Academy of Pharmacy. As entrepreneur, she has promoted the foundation of three companies (Pharmatools Digital Interactive SL, Allelyus and Oncostellae). She has been selected as one of the “30 scientists from 30 countries in Europe” of the Portraits of Science-Scientists of Tomorrow Initiative, in the 30th anniversary of the European Federation of Pharmaceutical Industries and Associations (EFPIA). She was recognized with the Innovative Researcher 2018 award by the FEI Recognitions.

LORENZO POLENZANI

He conducted research activities in cardiovascular diseases area at the Department of Preclinical and Clinical Pharmacology University of Florence. In 1988 he moved to University of California Irvine (USA) studying GABA receptors by means of molecular biology and electrophysiological techniques. Back to Italy in 1992, after a brief experience at the Biophysics Lab of the Cancer Institute Regina Elena Rome, he joined Angelini in 1993 as Head of the Molecular and Cellular Pharmacology Lab. In 2001 he became the Therapeutic Area Team leader of Analgesic and Anti-inflammatory products and then R&D Pipeline Strategy Manager. Since 2016, he is the Head of the Scientific Networking and Competitive Intelligence Unit of the Angelini’s RR&D (Research Regulatory and Development) looking for and evaluating innovative solutions and technological platforms to be considered for research collaboration and licensing operations. Member of the Italian Society of Pharmacology (SIF) and International Association for the Study of Pain (IASP).

YVES GEYSELS

Yves Geysels is Visiting Professor of Clinical Trials at the Faculty of Medicine, Department of Biomedical Sciences and has authored more than 50 publications. Currently he is also Director of Clinical Operations at Bone Therapeutics, a bone cell therapy company, specializing in addressing unmet medical needs in the field of orthopaedics and bone diseases. Yves has a vast experience of more than 20 years in managing clinical trials from an operational point of view, within pharmaceutical companies and Contract Research Organizations (CRO), prior joining the Biotech Industry in 2018. He is founder and honorary president of the Belgian Association of Clinical Research Professionals (ACRP.be) and a honorary fellow at the University of Brussels (VUB).

CRISTINA CARREÑO

Dr. Cristina Carreño is the Business Development Director of Lipotec, the active ingredients division of Lubrizol. She received her PhD in Organic Chemistry from the University of Barcelona in 1997, where she specialized in both peptide and combinatorial chemistry. For nine years she was in charge of the Peptide Synthesis Facility at the University of Barcelona, after which she joined to DiverDrugs, the research company of Lipotec Group. Initially focused on the discovery of new active ingredients for the pharmaceutical field, from 2004 to 2011 she was responsible of the development of new active ingredients for cosmetic applications. Since 2008 she combined her activities in DiverDrugs with the development of new business for Lipotec on a global basis, managing strategic collaborations with regional and global cosmetic companies. Since end 2011 she works for Lipotec on an exclusive basis, being accountable for accelerating the active ingredients business and for the continuous education program for Lubrizol marketing and sales force in the Beauty division. Dr. Carreño is the author of several patents in the field of new actives for cosmetic dermatology.

CLAIRE DACHELET

Claire Dachelet, MD, was graduated from the faculty of medicine and obtained the complementary master of Dermato-Venereology in 1998 (University of Namur and University Catholic of Louvain UCL – Brussels). During her residency, she worked in the Laboratory of Dermatology for the diagnosis of autoimmune bullous diseases, connective tissue diseases and vasculitis. She was trained as a research fellow at the University of Washington, Seattle in 1997-1998. She obtained in 2010 a DU in Infectious and Tropical Dermatology from the University Pierre and Marie Curie, Paris. In 1998, she joined the UCL Laboratory of Dermatology and developed the diagnosis of auto-immune skin diseases. She started a clinical activity at the CHU of Mont-Godinne. In 2006, she became the head of the department of Dermatology of the CHU UCL Namur – Godinne. Currently, she has been working for the CHU UCL Namur and for the Anatomical Pathology Laboratory of UCL. She is a dermatology training master for 6 years.

Her main fields of activity are:

  • Autoimmune bullous diseases
  • Auto-immune and auto-inflammatory diseases
  • Immunocompromised patients
  • Infectious and tropical dermatology

Student – Academic Staff Committee (SASC)

It is composed of three members of academic staff (one from each institution) and three elected students per each intake. It is called upon in two ways: (i) students use this Committee to bring formally to the attention issues to the management; (ii) the Committee gives a non-binding judgement on the changes proposed by the JCB. Student elections will be overseen by the JCB. SACS meets once a year.

Secretariat

It deals with the management of the course, regarding economic, administrative and practical issues of EMOTION. It is responsible for the Programme website, processes all applications, organizes the Joint Admission Board and the Joint Examination Board, prepares the joint diploma supplement, coordinates the production of the promotion/dissemination material. A Project Manager, member of the administration of UPO, is formally appointed to manage the Master from an institutional point of view, coordinates  the Secreteriat and is assisted by a junior Project Manager that will work specifically on EMOTION. The Project Manager may be co-opted as a non-voting member in the JCB. HU and UMH name technical support staff members that lease with the secretariat regarding general management issues and deal with specific issues of the teaching held in the respective Institutions. The secretariat meets UH and UMH technical support staff members in person or through electronically-mediated systems at least once per year.

Alongside, a number of activities through the year will take place to ensure quality assurance, excellence and continuous improvement of the course (e.g. student feedback at the end of each lesson and/or teaching module; alumni questionnaire).

Last modified: April 23, 2019